fashion -WSS

fashion

author：Wikipedia 2025-09-28 18:30:51 - browse：2499

Two people run on the sugar-phosphate backbone of DNA while holding base pairs — in the lab coverage from STAT — Adobe

LONDON — Widespread genetic testing as well as the development of cutting-edge, customized genetic therapies have opened the door to treating many more inherited conditions than previously possible. A few recent cases, in which bespoke medicines were created for children with exceedingly rare mutations, have raised hopes for furthering the approach.

Now, researchers and government agencies in the U.K. are trying to figure out the nitty-gritty to replicate those early one-off successes for as many patients as possible — what sort of preclinical testing a tailor-made treatment needs to go through before being used, what regulatory thresholds each treatment needs to clear, and how to pay for these therapies.

“A lot of the barriers are no longer scientific — we can make these drugs,” said Matthew Wood, a professor of pediatrics at the University of Oxford. “It’s more about, can we make them at a cost that is reasonable enough? And can we get the regulators to reduce the barriers to doing this so that when a patient shows up, you can actually make a drug quickly enough to benefit that patient, rather than it costing huge amounts of money and taking two or three years to do it?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Unmasking the 'centricity' illusion in clinical trials

explore

WSS

Medical students need to learn the potent medicine of empathy

Asahi Kasei to buy Calliditas, picking up kidney disease drug

NIH tests clinical research in primary care with $30 million program

The Bio Revolution is changing business and society

'Essentially witchcraft:' A former naturopath takes on the field

Beyond aggravation: Constipation is an American epidemic

explore

fashion

focus

After affirmative action ruling, medical educators look to 'holistic review'

Readers discuss the intersection of pregnancy and addiction

Moonlake's readout produced a cash windfall. Risks remain

Study: Why relieving medical debt did not improve financial outcomes

In age of alternative facts, a scholarly course on calling out crap

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Dobbs anniversary: the lost opportunity of abortion as health care

Health care court cases: Humana, Sutter, Novant

Wildfire smoke exposes gaps in outdoor worker protections

Stephen Quake on the Chan Zuckerberg quest to conquer disease

explore

California wildfire smoke linked to 52,000 early deaths, study says

Medical device trials still don't enroll enough women, study finds

California wildfire smoke linked to 52,000 early deaths, study says

Health care court cases: Humana, Sutter, Novant

Lilly's Alzheimer's drug donanemab backed by FDA advisers

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

hotspot

entertainment

explore

Wikipedia